Xbrane Biopharma AB (publ) (STO:XBRANE)
Sweden
· Delayed Price · Currency is SEK 0.2235
-0.0080 (-3.46%)
Mar 28, 2025, 1:59 PM CET
Xbrane Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 198.72 | 238.73 | 57.62 | 10.71 | - | Upgrade
|
| Revenue | 198.72 | 238.73 | 57.62 | 10.71 | - | Upgrade
|
| Revenue Growth (YoY) | -16.76% | 314.33% | 438.03% | - | - | Upgrade
|
| Cost of Revenue | 18.23 | 203.34 | - | - | - | Upgrade
|
| Gross Profit | 180.5 | 35.39 | 57.62 | 10.71 | - | Upgrade
|
| Selling, General & Admin | 40.11 | 40.03 | 31.54 | 31.4 | 26.51 | Upgrade
|
| Research & Development | 312.89 | 305.78 | 199.65 | 160.62 | 197.28 | Upgrade
|
| Other Operating Expenses | 46.34 | -13.71 | -20.91 | -4.85 | -7.14 | Upgrade
|
| Operating Expenses | 399.34 | 332.11 | 210.27 | 187.17 | 216.65 | Upgrade
|
| Operating Income | -218.84 | -296.72 | -152.65 | -176.46 | -216.65 | Upgrade
|
| Interest Expense | -35.51 | -18.5 | -2.58 | -2.64 | -0.69 | Upgrade
|
| Interest & Investment Income | - | 2.41 | 0.3 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 0.92 | -9.15 | -13.56 | -4.13 | -0.79 | Upgrade
|
| Other Non Operating Income (Expenses) | - | -0.06 | -0.01 | -0.01 | - | Upgrade
|
| Pretax Income | -253.43 | -322.03 | -168.51 | -183.23 | -218.13 | Upgrade
|
| Income Tax Expense | 11.59 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -265.02 | -322.03 | -168.51 | -183.23 | -218.13 | Upgrade
|
| Earnings From Discontinued Operations | -1.2 | -66.14 | -4 | -5.15 | -7.9 | Upgrade
|
| Net Income | -266.22 | -388.17 | -172.51 | -188.38 | -226.03 | Upgrade
|
| Net Income to Common | -266.22 | -388.17 | -172.51 | -188.38 | -226.03 | Upgrade
|
| Shares Outstanding (Basic) | 1,230 | 29 | 26 | 24 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 1,230 | 29 | 26 | 24 | 18 | Upgrade
|
| Shares Change (YoY) | 4184.58% | 12.26% | 8.38% | 30.25% | 61.86% | Upgrade
|
| EPS (Basic) | -0.22 | -13.52 | -6.75 | -7.98 | -12.48 | Upgrade
|
| EPS (Diluted) | -0.22 | -13.52 | -6.75 | -7.99 | -12.48 | Upgrade
|
| Free Cash Flow | -134.23 | -413.47 | -205.53 | -247.29 | -242.26 | Upgrade
|
| Free Cash Flow Per Share | -0.11 | -14.40 | -8.04 | -10.48 | -13.38 | Upgrade
|
| Gross Margin | 90.83% | 14.82% | 100.00% | 100.00% | - | Upgrade
|
| Operating Margin | -110.12% | -124.29% | -264.94% | -1647.75% | - | Upgrade
|
| Profit Margin | -133.97% | -162.60% | -299.41% | -1759.04% | - | Upgrade
|
| Free Cash Flow Margin | -67.55% | -173.20% | -356.72% | -2309.16% | - | Upgrade
|
| EBITDA | -182.89 | -287.62 | -145.21 | -171.93 | -214.07 | Upgrade
|
| EBITDA Margin | -92.03% | -120.48% | -252.03% | - | - | Upgrade
|
| D&A For EBITDA | 35.95 | 9.1 | 7.44 | 4.53 | 2.57 | Upgrade
|
| EBIT | -218.84 | -296.72 | -152.65 | -176.46 | -216.65 | Upgrade
|
| EBIT Margin | -110.12% | -124.29% | -264.94% | - | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.